Company: ZVRA
Filing Date: 2025-11-20
Form Type: 8-K
Source: 0001193125-25-289865
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-20
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “ Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “ Separation Date”), in order to pursue other professional opportunities.

In connection with Mr. Clifton’s resignation, the Company and Mr. Clifton entered into a Separation Agreement and General Release (the “ Separation Agreement”). Pursuant to the Separation Agreement, following the Separation Date, Mr. Clifton will receive the separation benefits consisting of (i) an amount equal to 12 months of his annual base salary, payable in accordance with the Company’s normal payroll schedule, (ii) an annual bonus of 40% of his base salary, (iii) up to 12 months of Company-paid COBRA continuation coverage, and (iv) full vesting of his outstanding equity awards.

The payments and benefits under the Separation Agreement are contingent upon Mr. Clifton’s continued compliance with certain restrictive covenants, including non-disparagement, confidentiality, non-competition, and non-solicitationprovisions.

The Company has commenced a search process to identify a chief financial officer.